Global Milbexime Anthelmintic Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Milbexime Anthelmintic Market Research Report 2024
Similar to other macrolide antiparasitic drugs, milbexime acts as an agonist of GABA (γ-aminobutyric acid) neurotransmitter in nerve cells, and can also interact with gluten in nerve and muscle cells of invertebrates Amino acid-gated Cl-channel binding. In both cases, it blocks the parasite's nerve signaling, eventually paralyzing the parasite, causing the muscles to lose their ability to contract, stop feeding, and cause the parasite to die. Milbexime also affects the reproductive activity of some parasites by reducing oviposition or inducing abnormal egg production.
According to Mr Accuracy reports’s new survey, global Milbexime Anthelmintic market is projected to reach US$ 938 million in 2029, increasing from US$ 628 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Milbexime Anthelmintic market research.
Key manufacturers engaged in the Milbexime Anthelmintic industry include Elanco Animal Health, Boehringer Ingelheim Animal Health, Merck Animal Health, VIRBAC SA, Krka and Zhejiang Hisun Pharmaceutical Co., Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Milbexime Anthelmintic were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Milbexime Anthelmintic market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Milbexime Anthelmintic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Elanco Animal Health
Boehringer Ingelheim Animal Health
Merck Animal Health
VIRBAC SA
Krka
Zhejiang Hisun Pharmaceutical Co., Ltd
Segment by Type
Single Ingredient
Compound Ingredients
Cat
Dog
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Milbexime Anthelmintic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Milbexime Anthelmintic market is projected to reach US$ 938 million in 2029, increasing from US$ 628 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Milbexime Anthelmintic market research.
Key manufacturers engaged in the Milbexime Anthelmintic industry include Elanco Animal Health, Boehringer Ingelheim Animal Health, Merck Animal Health, VIRBAC SA, Krka and Zhejiang Hisun Pharmaceutical Co., Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Milbexime Anthelmintic were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Milbexime Anthelmintic market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Milbexime Anthelmintic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Elanco Animal Health
Boehringer Ingelheim Animal Health
Merck Animal Health
VIRBAC SA
Krka
Zhejiang Hisun Pharmaceutical Co., Ltd
Segment by Type
Single Ingredient
Compound Ingredients
Segment by Application
Cat
Dog
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Milbexime Anthelmintic report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices